GlassScriptPhysician profile
Anthony Montemuro
NPI 1578597902
$4,988.09
in general payments reported to CMS, 2019-2025
36 companies · $742 in 2025
The $742 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $447 · 2020: $405 · 2021: $1,344 · 2022: $1,105 · 2023: $493 · 2024: $452 · 2025: $742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,672 · Education: $15.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,671.88 |
| Education | $15.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,119.39 | 2019-2025 | |
| Gilead Sciences, INC. | $460.38 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $375.98 | 2019-2023 | Trulance |
| Qol Medical, LLC | $321.78 | 2019-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $281.61 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Merck Sharp & Dohme LLC | $193.49 | 2019-2022 | |
| Ardelyx, INC. | $181.42 | 2023-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $114.42 | 2019-2025 | |
| Shionogi INC | $97.52 | 2019 | |
| Medtronic, INC. | $91.81 | 2021-2024 | Endoflip, Het |
| Daiichi Sankyo INC. | $71.32 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $69.08 | 2021-2023 | |
| Allergan, INC. | $60.41 | 2020 | |
| Ironwood Pharmaceuticals, INC | $59.32 | 2019-2021 | |
| Evoke Pharma, INC. | $45.25 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $44.92 | 2021-2022 | |
| Pfizer INC. | $43.21 | 2022 | |
| Braintree Laboratories, INC. | $42.55 | 2020-2021 | |
| Fresenius Kabi USA, LLC | $27.61 | 2023 | |
| Intercept Pharmaceuticals, INC. | $25.85 | 2025 | |
| Shield Therapeutics INC | $24.61 | 2024 | |
| Mauna Kea Technologies, INC. | $21.68 | 2025 | |
| Alnylam Pharmaceuticals INC. | $21.37 | 2022 | |
| Capsovision, INC. | $20.34 | 2025 | Capsocam Plus |
| Lilly USA, LLC | $19.99 | 2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $19.10 | 2025 | Voquezna |
| Ethicon US, LLC | $18.92 | 2021 | |
| Novo Nordisk INC | $18.60 | 2025 | Wegovy |
| Endogastric Solutions, INC | $18.18 | 2022 | |
| Celgene Corporation | $17.70 | 2021 | |
| Amgen INC. | $15.44 | 2022 | |
| Genzyme Corporation | $13.37 | 2022 | |
| Ucb, INC. | $12.38 | 2019 | |
| Covidien LP | $11.29 | 2020 | |
| Dynavax Technologies Corporation | $4.05 | 2024 | Heplisav-B |
| Echosens North America, INC. | $3.75 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Montemuro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.